BSE filing, BSE: 544141. Summary written from the filing by ALFA Finder's alert engine.
Pune E-Stock Broking Ltd: key numbers
- Share price
- ₹261.00
- Market cap
- ₹408.5 Cr
- Revenue (annual)
- ₹53.87 Cr
- Net profit (annual)
- ₹19.56 Cr
- P/E (TTM)
- 20.9×Sector 19.7×
- Promoter holding
- 50.79%
- FII holding
- 0.49%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pune E-Stock Broking Ltd
All →Pune E-Stock Broking Board Meeting Date
Pune E-Stock Broking Limited intimated that its Board will meet on 30 Oct 2026 to consider half-yearly financial results and related-party transactions. No financial figures or decisions are reported in this advance notice.
Pune E-Stock Broking Other Announcement
Pune E - Stock Broking Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b). This discloses the distribution of shareholding among various investor categories.
Pune E-Stock Broking Fund Raise of ₹50 Cr
Pune E-Stock Broking Limited's board has approved raising up to ₹50 Crore through the issuance of Non-Convertible Debentures (NCDs). The secured debt will be issued on a private placement basis.
- Value
- ₹50.00 Cr
- Execution
- within a period of one year from the date of passing of the relevant Board Resolution
Pune E-Stock Broking Board Meeting Date
Pune E Stock Broking Limited has scheduled a board meeting for October 5, 2026. The board will consider a proposal for fund raising via a debt issue.
Pune E-Stock Broking Board Meeting Date
Pune E-Stock Broking Ltd scheduled a board meeting for October 05, 2026. The board will consider raising up to Rs. 50 Crore via NCDs.
- Value
- ₹50.00 Cr
Pune E-Stock Broking Annual General Meeting
Pune E-Stock Broking Limited held its 19th Annual General Meeting on September 10, 2026, where shareholders transacted business, including the adoption of financial statements and dividend declaration.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.